Not Yet Recruiting PHASE1 INTERVENTIONAL 6-arm
NCT06954818
Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More
A Randomized, Observer-blind, Placebo-controlled, Adaptive Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of SYS6017(a Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years or More
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions
Herpes Zoster
Interventions
A zoster mRNA vaccine SYS6017 Placebo
Updated 1 time since 2025 Last updated: May 5, 2025 Started: May 10, 2025 Primary completion: Dec 10, 2025 Completion: Nov 10, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06954818, this PHASE1 trial focuses on Herpes Zoster and remains actively recruiting participants. Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Data source: CSPC Megalith Biopharmaceutical Co.,Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.